| Name | Title | Contact Details |
|---|
wastrategy is a Chicago, IL-based company in the Business Services sector.
Hospice Of Holland Home is a Grand Rapids, MI-based company in the Business Services sector.
Grove Point Marinas is a Miami-based investment company that acquires and operates high-quality marinas across the United States. They offer bespoke Mergers and Acquisition services to their elite, global clientele.
Summa Linguae Technologies is a language and technology service provider headquartered in Poland with 7 offices located across North America, Europe, and Asia. We specialize in technology-enabled localization, managed services, and data solutions. Intent on transforming the traditional approach to language, Summa Linguae is one of the industrys fastest-growing companies. We take an outcome-based approach, tailoring solutions to our customers specific needs. Our promise is to help global, content-rich companies with every multilingual data challenge. To learn more about Summa Linguae Technologies, our journey, and the solutions we offer, visit: https://summalinguae.com/.
At enGene, we are at the vanguard of a new era in genetic medicine: Our novel Dually Derivatized Oligochitosan® (DDX) gene delivery platform is designed to enable localized delivery of multiple gene cargos, including RNA and DNA, directly to mucosal tissues and other organs — potentially overcoming the limitations of viral-based gene therapies and advancing gene therapy beyond rare genetic diseases into the mainstream of clinical practice. Our breakthrough Dually Derivatized Oligochitosan® (DDX) platform opens possibilities for streamlining the use of genetic medicines in the treatment of serious diseases, especially diseases afflicting mucosal tissues. Our lead product candidate, EG-70 (detalimogene voraplasmid), is a non-viral immunotherapy in development to treat non-muscle invasive bladder cancer (NMIBC), a disease with a significant patient burden, high clinical needs, and massive healthcare system economic impact. Based on its preliminary efficacy and safety profile and ease of administration by urologists, EG-70, which is currently in a pivotal trial, can potentially benefit patients across a wide variety of clinical settings. As enGeneers, we are boldly focused on patients needs. We are a team of passionate experts with extensive experience in drug development and commercialization across oncology, respiratory, and several other therapeutic areas. Nasdaq: ENGN